Tower Research Capital (TRC)’s Cardiff Oncology CRDF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.8K | Buy |
12,246
+6,257
| +104% | +$12.8K | ﹤0.01% | 3488 |
|
|
2025
Q4 | $16.8K | Sell |
5,989
-3,754
| -39% | -$8.72K | ﹤0.01% | 3233 |
|
|
2025
Q3 | $20.1K | Buy |
9,743
+1,892
| +24% | +$5.23K | ﹤0.01% | 3307 |
|
|
2025
Q2 | $24.7K | Buy |
7,851
+3,560
| +83% | +$10.9K | ﹤0.01% | 3551 |
|
|
2025
Q1 | $13.5K | Sell |
4,291
-1,586
| -27% | -$6.27K | ﹤0.01% | 3362 |
|
|
2024
Q4 | $25.5K | Buy |
5,877
+1,180
| +25% | +$3.69K | ﹤0.01% | 3004 |
|
|
2024
Q3 | $12.5K | Sell |
4,697
-28,021
| -86% | -$66.2K | ﹤0.01% | 3577 |
|
|
2024
Q2 | $72.6K | Buy |
32,718
+29,313
| +861% | +$110K | ﹤0.01% | 2819 |
|
|
2024
Q1 | $18.2K | Buy |
+3,405
| New | +$9.05K | ﹤0.01% | 3082 |
|
|
2023
Q4 | – | Sell |
-360
| Closed | -$500 | – | 5953 |
|
|
2023
Q3 | $500 | Buy |
+360
| New | +$607 | ﹤0.01% | 5549 |
|
|
2023
Q2 | – | Sell |
-392
| Closed | -$1K | – | 6073 |
|
|
2023
Q1 | $1K | Buy |
392
+72
| +23% | +$124 | ﹤0.01% | 5511 |
|
|
2022
Q4 | $0 | Buy |
+320
| New | +$458 | ﹤0.01% | 5947 |
|
|
2022
Q3 | – | Sell |
-388
| Closed | -$1K | – | 6112 |
|
|
2022
Q2 | $1K | Sell |
388
-24,028
| -98% | -$40.2K | ﹤0.01% | 5758 |
|
|
2022
Q1 | $60K | Buy |
24,416
+21,421
| +715% | +$75.8K | ﹤0.01% | 2588 |
|
|
2021
Q4 | $18K | Sell |
2,995
-9,185
| -75% | -$54.7K | ﹤0.01% | 3781 |
|
|
2021
Q3 | $82K | Sell |
12,180
-6,837
| -36% | -$42.9K | ﹤0.01% | 2564 |
|
|
2021
Q2 | $126K | Buy |
+19,017
| New | +$161K | ﹤0.01% | 2233 |
|
|
2021
Q1 | – | Sell |
-75
| Closed | -$1K | – | 5434 |
|
|
2020
Q4 | $1K | Sell |
75
-3,435
| -98% | -$60.4K | ﹤0.01% | 4980 |
|
|
2020
Q3 | $50K | Buy |
+3,510
| New | +$23.2K | ﹤0.01% | 3540 |
|
|
2017
Q3 | – | Sell |
-74
| Closed | -$7K | – | 3817 |
|
|
2017
Q2 | $7K | Sell |
74
-540
| -88% | -$34.8K | ﹤0.01% | 1800 |
|
|
2017
Q1 | $51K | Buy |
614
+595
| +3,132% | +$80.8K | 0.01% | 721 |
|
|
2016
Q4 | $3K | Buy |
19
+4
| +27% | +$934 | ﹤0.01% | 3234 |
|
|
2016
Q3 | $5K | Hold |
15
| – | – | ﹤0.01% | 2526 |
|
|
2016
Q2 | $5K | Buy |
+15
| New | +$5.17K | ﹤0.01% | 3355 |
|
|
2016
Q1 | – | Sell |
-27
| Closed | -$11K | – | 4217 |
|
|
2015
Q4 | $11K | Sell |
27
-17
| -39% | -$6.66K | ﹤0.01% | 1992 |
|
|
2015
Q3 | $18K | Buy |
44
+7
| +19% | +$3.66K | ﹤0.01% | 1815 |
|
|
2015
Q2 | $27K | Hold |
37
| – | – | ﹤0.01% | 1835 |
|
|
2015
Q1 | $18K | Buy |
37
+33
| +825% | +$14.1K | ﹤0.01% | 2329 |
|
|
2014
Q4 | $1K | Sell |
4
-54
| -93% | -$17.5K | ﹤0.01% | 3615 |
|
|
2014
Q3 | $19K | Buy |
+58
| New | +$17.4K | ﹤0.01% | 2334 |
|
|
2014
Q2 | – | Sell |
-72
| Closed | -$30K | – | 4093 |
|
|
2014
Q1 | $30K | Sell |
72
-74
| -51% | -$32K | ﹤0.01% | 1492 |
|
|
2013
Q4 | $60K | Buy |
146
+110
| +306% | +$49K | 0.01% | 1238 |
|
|
2013
Q3 | $19K | Sell |
36
-1
| -3% | -$569 | ﹤0.01% | 2719 |
|
|
2013
Q2 | $19K | Buy |
+37
| New | +$16.7K | ﹤0.01% | 1756 |
|
Other funds holding CRDF
VCM
LCM
P
ACA
FLPIM
Tower Research Capital (TRC)'s CRDF Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Cardiff Oncology (CRDF) stake by 104% in Q1 2026, buying an estimated $12.8K and bringing the position to 12,246 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3488.
Tower Research Capital (TRC) first reported a position in CRDF in Q2 2013 and has held it in 34 quarters since. The position peaked at $126K in Q2 2021. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.
- Tower Research Capital (TRC) held 12,246 shares of Cardiff Oncology worth $19.8K as of Q1 2026.
- Tower Research Capital (TRC) bought 6,257 Cardiff Oncology shares in Q1 2026, an estimated $12.8K.
- Cardiff Oncology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3488 holding.
- Tower Research Capital (TRC) first reported a position in Cardiff Oncology in Q2 2013 and has held it in 34 quarters since.
- Tower Research Capital (TRC)'s Cardiff Oncology position peaked at $126K in Q2 2021.
- 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.